Cargando…
Mechanisms of immune evasion and current status of checkpoint inhibitors in non‐small cell lung cancer
In the past several years, immunotherapy has emerged as a viable treatment option for patients with advanced non‐small cell lung cancer (NSCLC) without actionable driver mutations that have progressed on standard chemotherapy. We are also beginning to understand the methods of immune evasion employe...
| Autores principales: | , , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
John Wiley and Sons Inc.
2016
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5055165/ https://www.ncbi.nlm.nih.gov/pubmed/27416962 http://dx.doi.org/10.1002/cam4.819 |